AX 1826
Latest Information Update: 04 Oct 2004
Price :
$50 *
At a glance
- Originator Ajinomoto
- Class
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 30 Sep 2004 Discontinued - Preclinical for Thrombosis in Japan (unspecified route)
- 07 Jan 2004 No development reported - Preclinical for Thrombosis in Japan (unspecified route)
- 09 Jun 2000 New profile